Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Ho GY, Kyran EL, Bedo J, Wakefield MJ, Ennis DP, Mirza HB, Vandenberg CJ, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey UM, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV; Scottish Genomes Partnership; Cooke SL, Ratnayake G, McNally O, Traficante N; Australian Ovarian Cancer Study12,13; DeFazio A, Weroha SJ, Bowtell DD, McNeish IA, Papenfuss AT, Scott CL, Barker HE. Ho GY, et al. Among authors: roxburgh p. Cancer Res. 2022 Dec 2;82(23):4457-4473. doi: 10.1158/0008-5472.CAN-21-4012. Cancer Res. 2022. PMID: 36206301 Free PMC article.
Squamous carcinoma of the ovary.
Roxburgh P, Glasspool R. Roxburgh P, et al. Curr Oncol Rep. 2014 Dec;16(12):413. doi: 10.1007/s11912-014-0413-1. Curr Oncol Rep. 2014. PMID: 25344339 Review.
Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma.
Ewing A, Meynert A, Churchman M, Grimes GR, Hollis RL, Herrington CS, Rye T, Bartos C, Croy I, Ferguson M, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, Ennis D, McMahon L, Matakidou A, Dougherty B, March R, Barrett JC, McNeish IA; Scottish Genomes Partnership; Biankin AV, Roxburgh P, Gourley C, Semple CA. Ewing A, et al. Among authors: roxburgh p. Clin Cancer Res. 2021 Jun 1;27(11):3201-3214. doi: 10.1158/1078-0432.CCR-20-4068. Epub 2021 Mar 19. Clin Cancer Res. 2021. PMID: 33741650 Free PMC article.
Metronomic oral cyclophosphamide in relapsed ovarian cancer.
Spiliopoulou P, Hinsley S, McNeish IA, Roxburgh P, Glasspool R. Spiliopoulou P, et al. Among authors: roxburgh p. Int J Gynecol Cancer. 2021 Jul;31(7):1037-1044. doi: 10.1136/ijgc-2021-002467. Epub 2021 May 20. Int J Gynecol Cancer. 2021. PMID: 34016703 Free article.
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
Moreno V, Barretina-Ginesta MP, García-Donas J, Jayson GC, Roxburgh P, Vázquez RM, Michael A, Antón-Torres A, Brown R, Krige D, Champion B, McNeish I. Moreno V, et al. Among authors: roxburgh p. J Immunother Cancer. 2021 Dec;9(12):e003645. doi: 10.1136/jitc-2021-003645. J Immunother Cancer. 2021. PMID: 34893524 Free PMC article. Clinical Trial.
Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.
Spiliopoulou P, Spear S, Mirza H, Garner I, McGarry L, Grundland-Freile F, Cheng Z, Ennis DP, Iyer N, McNamara S, Natoli M, Mason S, Blyth K, Adams PD, Roxburgh P, Fuchter MJ, Brown B, McNeish IA. Spiliopoulou P, et al. Among authors: roxburgh p. Mol Cancer Ther. 2022 Apr 1;21(4):522-534. doi: 10.1158/1535-7163.MCT-21-0743. Mol Cancer Ther. 2022. PMID: 35131874 Free PMC article.
CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.
Wohlmuth C, Djedovic V, Kjaer SK, Jensen A, Glasspool R, Roxburgh P, DeFazio A, Johnatty SE, Webb PM, Modugno F, Lambrechts D, Schildkraut JM, Berchuck A, Thomsen LCV, Bjorge L, Høgdall E, Høgdall CK, Goode EL, Winham SJ, Matsuo K, Karlan BY, Lester J, Goodman MT, Thompson PJ, Pejovic T, Riggan MJ, Lajkosz K, Tone A, May T. Wohlmuth C, et al. Among authors: roxburgh p. Cancers (Basel). 2022 Apr 13;14(8):1954. doi: 10.3390/cancers14081954. Cancers (Basel). 2022. PMID: 35454861 Free PMC article.
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, de Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M; Gynecologic Cancer InterGroup (GCIG) symptom benefit committee. Kurtz JE, et al. Among authors: roxburgh p. Gynecol Oncol. 2021 May;161(2):502-507. doi: 10.1016/j.ygyno.2021.02.018. Epub 2021 Feb 19. Gynecol Oncol. 2021. PMID: 33612336 Review.
38 results